In the latest market close, Eli Lilly (LLY) reached $887.16, with a +0.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.Shares of the drugmaker have depreciated by 2.98% over the course of the past month, outperforming the Medical sector's loss of 4.05% and lagging the S&P 500's gain of 3.15%.The upcoming earnings release of Eli Lilly will be of great interest to investors. It is anticipated ...

Thursday, The FDA determined the shortage of Eli Lilly And Co’s LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs.The FDA noted that Novo Nordisk A/S‘ NVO semaglutide (Wegovy, Ozempic) is still in shortage.Despite semaglutide being the active ing ...

Eli Lilly and Company (LLY) announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable the development of new methods for making its drugs and also scale up the supply of medicines for clinical trials for Lilly’s growing pipeline. This one-of-a-kind facility, which combines research and manufacturing in a single location, will open in 2027.The Medicine Foundry, which is expected to create ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Eli Lilly (LLY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Eli Lilly is a member of our Medical group, which includes 1025 different companie ...

The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages. The initial shortage led the FDA to permit pharmacies to sell less-tested generic versions. Eli Lilly has been increasing investments to boost medication supply, including constructing a ne ...

The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.Mounjaro, which is primarily used for diabetes treatment, and Zepbound, used for weight control, had been listed on the FDA's shortage list since late 2022 and Apri ...

文章核心观点 - 艾利利利公司将投资45亿美元建立一个名为"利利医药基地"的新中心,旨在寻找更好的制药方法 [1][2] - 该中心将结合研究和生产,在一个地点内完成从实验室到药房的全过程 [2] - 公司希望通过这一举措,进一步推动其在肥胖和减重药物Mounjaro和Zepbound的成功,并将其应用到其他管线产品中 [2][3] - 公司还计划加大在神经科学领域的投资,包括阿尔茨海默病和其他神经退行性疾病的研究 [4] 公司概况 - 公司正在建设一个价值90亿美元的制药原料生产基地,用于生产Mounjaro和Zepbound的活性成分 [2] - Mounjaro和Zepbound预计到2028年将带来500亿美元的收入,几乎是公司2022年全年收入的两倍 [3] - 公司希望利用这些收入,投资开发更多新药,包括阿尔茨海默病和神经退行性疾病等领域 [3][4] 行业趋势 - 公司表示,其他制药公司正在停止不同的研究项目,试图追赶公司在肥胖和阿尔茨海默病领域的领先地位 [3] - 公司希望在其已有优势的肿瘤和免疫学领域,以及心血管疾病、慢性疼痛和听力损失等新兴领域寻找"突破性想法" [3]

文章核心观点 - 公司将投资45亿美元在印第安纳州建立利利医药基地,这是一个集研究、制造和最新技术于一体的创新生产中心 [1][2] - 该设施将增强公司的工艺开发和扩大制造能力,以加快下一代药物的交付 [2] - 该设施将创造400个高技能工作岗位,包括工程师、科学家、操作人员和实验室技术人员 [3] - 这是公司在该地区的又一次大规模投资,自2020年以来在美国的总投资已超过230亿美元 [1][3] 根据目录分类总结 设施概况 - 该设施将于2027年底开始运营,位于印第安纳州的LEAP研究和创新区 [1] - 该设施将研究新的药品生产方法,同时扩大临床试验药品的生产规模 [1][2] - 该设施采用灵活的设计,可生产小分子药物、生物制品和核酸疗法等多种分子疗法 [2] - 该设施开发的新技术将转移到公司其他制造基地进行大规模生产 [2] 投资和就业 - 该项目将获得印第安纳州政府的基础设施改善和经济激励支持 [3] - 该设施投产后预计将创造400个高技能工作岗位 [3] - 这是公司在该地区的又一次大规模投资,自2020年以来在美国的总投资已超过230亿美元 [1][3]

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned -8.6% over the past month versus the Zacks S&P 500 composite's +2.1% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has lost 5.5% over this period. Now the key question is: Where could the stock be headed in the near term?Although me ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.With all the focus on Eli Lilly's (NYSE: LLY ) obesity business, the rec ...